Evaluate a Norstella company
Evaluate a Norstella company

Report

Commercializing Biotech

With emerging biopharma securing almost two-thirds of the FDA’s new drug approvals in 2024, what drives a decision to “go it alone” when it comes to commercialization – and what are the steps to success?

Find out in Evaluate’s latest report highlights – exclusive for Bio Spring delegates

Download this exclusive report.

Download Now



Recent Resources

Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.

April 21, 2026

How do Forecasting Approaches and Methodologies Change Through the Product Lifecycle?

Pharma forecasting is not a “one and done” activity. The life of a drug – from a glint in the clinician’s eye, to an established therapy heading towards loss of...

April 15, 2026

Meet the Team: Kelly Chamberlain

Kelly Chamberlain has been with Norstella, Evaluate’s parent company as Partner, Market Intelligence since 2024. She’s an expert in supporting competitive intelligence workflows and ensuring that CI teams can maximize...

March 31, 2026

BIO-Europe Spring: Pharma Dealmaking in Lisbon

CNS may finally be emerging from its long discussed graveyard. Oncology dealmaking is becoming more selective. And sourcing innovation from China is no longer something to be coy about. These...

March 30, 2026

Highlights of the Orphan Drugs Report by its Creators

For the past few years, Melanie Senior and Andreas Hadjivasiliou have worked together to deliver Evaluate’s annual Orphan Drugs report. They charted the rise and rise of drugs for rare...

March 30, 2026

How We Build the Analysis Behind Our Orphan Drugs Report

How do we Create the Analysis for our Orphan Drugs Report? Insight is the cornerstone of our annual orphan drugs report, and all that insight and analysis starts with the...

March 20, 2026

Three Things we Learned in our 2026 Orphan Drugs Webinar

Orphan drugs are forecast to make up 21% of all prescription drug sales by 2032, according to Evaluate forecasts. So it’s hardly surprising that we had a lot of interest...

Evaluate White Logo
Instagram Linkedin